SVRA
Savara Inc.
Biotechnology
Market Cap$904M
5Y Perf.+114.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
SVRA vs VTRS vs ABBV vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
VTRS
Viatris Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$19.99B
5Y Perf.+0.6%
ABBV
AbbVie Inc.
Drug Manufacturers - General
Market Cap$356.49B
5Y Perf.+117.5%
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$41.60B
5Y Perf.+185.2%
SVRA vs VTRS vs ABBV vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SVRA | VTRS | ABBV | TEVA |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| Market Cap | $904M | $19.99B | $356.49B | $41.60B |
| Revenue (TTM) | $0.00 | $14.56B | $61.16B | $17.35B |
| Net Income (TTM) | $-116M | $-296M | $4.23B | $1.56B |
| Gross Margin | — | 34.4% | 70.2% | 52.1% |
| Operating Margin | — | 1.0% | 26.7% | 13.2% |
| Forward P/E | — | 7.0x | 14.2x | 15.5x |
| Total Debt | $27M | $14.70B | $69.07B | $17.38B |
| Cash & Equiv. | $15M | $1.35B | $5.23B | $3.56B |
SVRA vs VTRS vs ABBV vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SVRA
VTRS
ABBV
TEVA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Savara Inc. (SVRA) | 100 | 214.3 | +114.3% |
| Viatris Inc. (VTRS) | 100 | 100.6 | +0.6% |
| AbbVie Inc. (ABBV) | 100 | 217.5 | +117.5% |
| Teva Pharmaceutical… (TEVA) | 100 | 285.2 | +185.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SVRA vs VTRS vs ABBV vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABBV and TEVA are tied at the top with 3 categories each — the right choice depends on your priorities. Teva Pharmaceutical Industries Limited is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. VTRS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SVRA
Savara Inc.
The Secondary Option
SVRA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
VTRS
Viatris Inc.
The Defensive Pick
VTRS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.94, Low D/E 99.9%, current ratio 1.30x
- Lower P/E (7.0x vs 15.5x)
Best for: sleep-well-at-night
ABBV
AbbVie Inc.
The Income Pick
ABBV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 13 yrs, beta 0.28, yield 3.3%
- Rev growth 8.6%, EPS growth -0.8%, 3Y rev CAGR 1.8%
- Beta 0.28, yield 3.3%, current ratio 0.67x
- 8.6% revenue growth vs SVRA's -39.5%
Best for: income & stability and growth exposure
TEVA
Teva Pharmaceutical Industries Limited
The Long-Run Compounder
TEVA is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- -28.8% 10Y total return vs ABBV's 293.8%
- 9.0% margin vs VTRS's -2.0%
- +97.7% vs ABBV's +12.2%
- 3.9% ROA vs SVRA's -82.1%, ROIC 7.7% vs -47.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABBV | 8.6% revenue growth vs SVRA's -39.5% |
| Value | VTRS | Lower P/E (7.0x vs 15.5x) |
| Quality / Margins | TEVA | 9.0% margin vs VTRS's -2.0% |
| Stability / Safety | ABBV | Beta 0.28 vs SVRA's 1.10 |
| Dividends | ABBV | 3.3% yield, 13-year raise streak, vs VTRS's 2.8%, (2 stocks pay no dividend) |
| Momentum (1Y) | TEVA | +97.7% vs ABBV's +12.2% |
| Efficiency (ROA) | TEVA | 3.9% ROA vs SVRA's -82.1%, ROIC 7.7% vs -47.9% |
SVRA vs VTRS vs ABBV vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2025
SVRA vs VTRS vs ABBV vs TEVA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLABBVLAGGINGSVRA
Who Leads Where
ABBV leads in 3 of 6 categories
VTRS leads 1 • TEVA leads 1 • SVRA leads 0 • 1 tied
Explore the data ↓SVRASavara Inc.
0leads
TEVATeva Pharmaceutical I…
1leads
VTRSViatris Inc.
1leads
ABBVAbbVie Inc.
3leads
6 Total Categories
CATEGORYLEADERvs VTRSvs TEVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ABBV5/6
Valuation MetricsMultiples, price ratios, and targets
VTRS4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ABBV4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
ABBV2/2
Income & Cash Flow (Last 12 Months)
ABBV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABBV and SVRA operate at a comparable scale, with $61.2B and $0 in trailing revenue. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to VTRS's -2.0%. On growth, ABBV holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SVRASavara Inc. | VTRSViatris Inc. | ABBVAbbVie Inc. | TEVATeva Pharmaceutic… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $14.6B | $61.2B | $17.3B |
| EBITDAEarnings before interest/tax | -$121M | $2.3B | $24.5B | $3.3B |
| Net IncomeAfter-tax profit | -$116M | -$296M | $4.2B | $1.6B |
| Free Cash FlowCash after capex | -$99M | $1.4B | $18.7B | $1.2B |
| Gross MarginGross profit ÷ Revenue | — | +34.4% | +70.2% | +52.1% |
| Operating MarginEBIT ÷ Revenue | — | +1.0% | +26.7% | +13.2% |
| Net MarginNet income ÷ Revenue | — | -2.0% | +6.9% | +9.0% |
| FCF MarginFCF ÷ Revenue | — | +9.3% | +30.6% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +8.1% | +10.0% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -27.3% | +105.9% | +57.4% | +72.2% |
ABBV leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
VTRS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 29.8x trailing earnings, TEVA trades at a 65% valuation discount to ABBV's 85.0x P/E. On an enterprise value basis, ABBV's 14.9x EV/EBITDA is more attractive than VTRS's 246.6x.
| Metric | SVRASavara Inc. | VTRSViatris Inc. | ABBVAbbVie Inc. | TEVATeva Pharmaceutic… |
|---|---|---|---|---|
| Market CapShares × price | $904M | $20.0B | $356.5B | $41.6B |
| Enterprise ValueMkt cap + debt − cash | $916M | $33.3B | $420.3B | $55.4B |
| Trailing P/EPrice ÷ TTM EPS | -10.90x | -5.72x | 85.04x | 29.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 6.98x | 14.17x | 15.50x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 246.65x | 14.89x | 17.55x |
| Price / SalesMarket cap ÷ Revenue | — | 1.40x | 5.83x | 2.41x |
| Price / BookPrice ÷ Book value/share | 6.05x | 1.37x | — | 5.30x |
| Price / FCFMarket cap ÷ FCF | — | 10.32x | 20.01x | 36.24x |
VTRS leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
ABBV leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-123 for SVRA. SVRA carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs SVRA's 2/9, reflecting strong financial health.
| Metric | SVRASavara Inc. | VTRSViatris Inc. | ABBVAbbVie Inc. | TEVATeva Pharmaceutic… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -122.5% | -2.0% | +62.1% | +20.7% |
| ROA (TTM)Return on assets | -82.1% | -0.8% | +3.1% | +3.9% |
| ROICReturn on invested capital | -47.9% | -6.6% | +23.9% | +7.7% |
| ROCEReturn on capital employed | -56.5% | -8.1% | +21.5% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.16x | 1.00x | — | 2.20x |
| Net DebtTotal debt minus cash | $12M | $13.4B | $63.8B | $13.8B |
| Cash & Equiv.Liquid assets | $15M | $1.3B | $5.2B | $3.6B |
| Total DebtShort + long-term debt | $27M | $14.7B | $69.1B | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | — | -0.51x | 3.28x | 2.51x |
ABBV leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,859 today (with dividends reinvested), compared to $12,992 for VTRS. Over the past 12 months, TEVA leads with a +97.7% total return vs ABBV's +12.2%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.0% vs ABBV's 14.4% — a key indicator of consistent wealth creation.
| Metric | SVRASavara Inc. | VTRSViatris Inc. | ABBVAbbVie Inc. | TEVATeva Pharmaceutic… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.3% | +38.8% | -10.6% | +15.4% |
| 1-Year ReturnPast 12 months | +62.4% | +94.2% | +12.2% | +97.7% |
| 3-Year ReturnCumulative with dividends | +166.8% | +89.5% | +49.7% | +294.4% |
| 5-Year ReturnCumulative with dividends | +228.9% | +29.9% | +99.6% | +248.6% |
| 10-Year ReturnCumulative with dividends | -40.3% | -52.1% | +293.8% | -28.8% |
| CAGR (3Y)Annualised 3-year return | +38.7% | +23.7% | +14.4% | +58.0% |
TEVA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VTRS and ABBV each lead in 1 of 2 comparable metrics.
Risk & Volatility
ABBV is the less volatile stock with a 0.28 beta — it tends to amplify market swings less than SVRA's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTRS currently trades 97.9% from its 52-week high vs SVRA's 74.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SVRASavara Inc. | VTRSViatris Inc. | ABBVAbbVie Inc. | TEVATeva Pharmaceutic… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 0.94x | 0.28x | 1.08x |
| 52-Week HighHighest price in past year | $7.00 | $17.53 | $244.81 | $37.35 |
| 52-Week LowLowest price in past year | $1.89 | $8.19 | $176.57 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +74.7% | +97.9% | +82.3% | +95.7% |
| RSI (14)Momentum oscillator 0–100 | 45.7 | 84.2 | 43.9 | 70.6 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 10.6M | 5.8M | 6.6M |
Evenly matched — VTRS and ABBV each lead in 1 of 2 comparable metrics.
Analyst Outlook
ABBV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SVRA as "Buy", VTRS as "Hold", ABBV as "Buy", TEVA as "Buy". Consensus price targets imply 91.2% upside for SVRA (target: $10) vs -5.4% for VTRS (target: $16). For income investors, ABBV offers the higher dividend yield at 3.26% vs VTRS's 2.79%.
| Metric | SVRASavara Inc. | VTRSViatris Inc. | ABBVAbbVie Inc. | TEVATeva Pharmaceutic… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $16.25 | $256.69 | $39.29 |
| # AnalystsCovering analysts | 11 | 12 | 41 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | +2.8% | +3.3% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 13 | 1 |
| Dividend / ShareAnnual DPS | — | $0.48 | $6.57 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +2.5% | +0.3% | 0.0% |
ABBV leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
ABBV leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VTRS leads in 1 (Valuation Metrics). 1 tied.
Best OverallAbbVie Inc. (ABBV)Leads 3 of 6 categories
Loading custom metrics...
SVRA vs VTRS vs ABBV vs TEVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SVRA or VTRS or ABBV or TEVA a better buy right now?
For growth investors, AbbVie Inc.
(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 29. 8x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Savara Inc. (SVRA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SVRA or VTRS or ABBV or TEVA?
On trailing P/E, Teva Pharmaceutical Industries Limited (TEVA) is the cheapest at 29.
8x versus AbbVie Inc. at 85. 0x. On forward P/E, Viatris Inc. is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SVRA or VTRS or ABBV or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +248.
6%, compared to +29. 9% for Viatris Inc. (VTRS). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus VTRS's -52. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SVRA or VTRS or ABBV or TEVA?
By beta (market sensitivity over 5 years), AbbVie Inc.
(ABBV) is the lower-risk stock at 0. 28β versus Savara Inc. 's 1. 10β — meaning SVRA is approximately 300% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Savara Inc. (SVRA) carries a lower debt/equity ratio of 16% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — SVRA or VTRS or ABBV or TEVA?
By revenue growth (latest reported year), AbbVie Inc.
(ABBV) is pulling ahead at 8. 6% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, TEVA leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SVRA or VTRS or ABBV or TEVA?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SVRA or VTRS or ABBV or TEVA more undervalued right now?
On forward earnings alone, Viatris Inc.
(VTRS) trades at 7. 0x forward P/E versus 15. 5x for Teva Pharmaceutical Industries Limited — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SVRA: 91. 2% to $10. 00.
08Which pays a better dividend — SVRA or VTRS or ABBV or TEVA?
In this comparison, ABBV (3.
3% yield), VTRS (2. 8% yield) pay a dividend. SVRA, TEVA do not pay a meaningful dividend and should not be held primarily for income.
09Is SVRA or VTRS or ABBV or TEVA better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc.
(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, SVRA: -40. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SVRA and VTRS and ABBV and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SVRA is a small-cap quality compounder stock; VTRS is a mid-cap quality compounder stock; ABBV is a large-cap income-oriented stock; TEVA is a mid-cap quality compounder stock. VTRS, ABBV pay a dividend while SVRA, TEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.